Answers are grounded in this paper and cite their sources.
Editorial highlights joint effects of diabetes and alcohol on liver disease outcomes, suggesting integrated care.
The global rise of steatotic liver disease (SLD) reflects the converging epidemics of metabolic dysfunction and alcohol use [1]. In North America and Europe, nearly 90% of adults consume alcohol and more than 10% engage in harmful drinking [2], while over 2 billion adults are living with overweight or obesity globally [3]. These trends rarely occur in isolation. Instead, the overlapping presence of overweight, diabetes and harmful alcohol intake is increasingly the norm rather than the exception. The redefinition of SLD acknowledges this reality by framing the disease as a spectrum rather than as mutually exclusive entities [4]. Nonetheless, how the co-existence of these risk factors interacts to shape clinical outcomes remains incompletely understood. In this context, Zhou et al. used large prospective cohorts to examine the joint effects of type 2 diabetes (T2D) and alcohol consumption across the SLD spectrum [5]. The authors show that co-exposure substantially increases both all-cause and liver-related mortality, with the highest risks observed in individuals with T2D and alcohol-related liver disease. Notably, a significant interaction between T2D and alcohol was observed for liver-related mortality, but not for all-cause mortality. A limitation to consider here is that steatosis and thereby SLD was primarily identified using the Fatty Liver Index rather than imaging or histology, while fibrosis risk was estimated using FIB-4 rather than direct assessment. Beyond confirming increased risk, this study offers two clinically important messages. First, glycaemic control is a key modifier of alcohol-related harm. Individuals with poorer glycaemic control experience higher mortality risks across all SLD categories, with the greatest burden observed in those with concurrent alcohol exposure. These findings highlight hyperglycaemia as an amplifier of hepatic injury and reinforce the importance of sustained glycaemic control as a central component of liver disease management. Second, the findings point to a gap in current clinical practice. Risk factors are often considered separately, whereas disease biology reflects their combined effects. Alcohol use may be under-recognised in diabetes care, and metabolic risk may be underappreciated in patients with alcohol-related liver disease. Moreover, risk is dynamic, and patients move along the SLD spectrum as alcohol intake and metabolic status fluctuate over time [6]. This argues for a shift towards integrated, longitudinal risk assessment rather than static categorisation. These observations align with prior cohort studies demonstrating supra-additive interactions between alcohol and overweight, and emerging evidence that genetic susceptibility further amplifies risk when combined with metabolic dysfunction and alcohol exposure [7-9]. These results also have implications for screening efforts to detect advanced liver disease. Identifying individuals with combined exposures, particularly those with T2D and alcohol use, may help define a high-risk population for targeted fibrosis assessment and early intervention [10]. Given that a substantial proportion of liver-related mortality appears attributable to these combined factors, such an approach could have meaningful clinical impact. In conclusion, this study reinforces a simple but important message: in SLD, metabolic dysfunction and alcohol do not act independently; they interact. Recognising and addressing this interplay offers an opportunity to move from fragmented care toward integrated strategies that better reflect the realities of modern liver disease. Stine Johansen: conceptualization, writing – original draft. Aleksander Krag: writing – review and editing. Mads Israelsen: writing – review and editing. Nikolaj Torp: writing – review and editing. The authors have nothing to report. The authors declare no conflicts of interest. A.K. has served as a speaker and/or consultant/advisory board for Novo Nordisk, Norgine, Medscape, Boehringer Ingelheim, GSK, W4Cure, Madrigal, all outside the submitted work. Research support to institution: Astra, Siemens, Nordic Bioscience, GSK, Echosens. Board member and co-founder Evido. This article is linked to Zhou et al. papers. To view this article, visit https://doi.org/10.1111/apt.70683. Data sharing not applicable to this article as no datasets were generated or analysed during the current study.
No takes yet. Share an insight, caveat, or question.
Johansen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: